Flea & tick prevention · The problem
The pill that promises protection —
and what it doesn't tell you
One consistent gap between what pet owners are told and what the data actually shows.
By Integrative Pet Parent · Part 1 of 3 · 5 min read · Research-backed
Every year, the same script. You bring your dog in for a check-up, the vet hands you a chewable, and you leave reassured your pet is protected. No one mentions the seizures. No one mentions the tens of thousands of adverse event reports. No one mentions that the company behind that product is still fighting billions in cancer lawsuits tied to another product it once called safe.
What the regulators actually said
In 2018, the FDA issued a formal safety alert on an entire class of flea and tick medications — the isoxazolines. Bravecto, NexGard, Simparica, Credelio. The alert confirmed these drugs can cause seizures, tremors, and loss of coordination, even in animals with no prior neurological history. The European Medicines Agency (EMA) tracks the same products and reached the same conclusion — its data showed even worse outcomes. The mechanism is straightforward: isoxazolines block chloride channels in a parasite's nervous system, but those same channels exist in the mammalian brain.
The numbers — click each to go deeper
FDA reports · US
32,000+
Adverse events logged 2013–2017, before pet owners were told
EMA vs FDA · deaths & seizures
7–10×
More in European data for the exact same drugs
Dogs with reactions · Project Jake
66.6%
Had adverse reactions in independent survey of 2,751 dogs
32,000+ reports — and five years of silence
From the moment isoxazoline products entered the US market in 2013, the FDA's post-market surveillance system began collecting reports of seizures, tremors, and neurological events. By September 2017 — before the FDA issued any public warning — over 32,000 reportable events had been logged for dogs alone.
The public warning came in 2018. The reports had been accumulating for five years before pet owners were told.
Why Europe's numbers are so much higher
The EMA and FDA received comparable total adverse event counts — but the European data showed 7–10× more deaths and seizures. Same drugs. Same formula. Two different surveillance systems, one drastically different severity picture.
This gap almost certainly reflects
better reporting in Europe, not worse outcomes — which means the US figures are very likely a significant undercount of the true harm.
Breaking down the 66.6%
The Project Jake Survey (2020) was independent of any manufacturer. Of 1,594 dogs given flea treatment, 83% received an isoxazoline. Two thirds experienced some adverse event — ranging from mild tremors to death.
The most serious adverse events appeared most commonly
within 24 hours of the first dose, with further peaks after the second and third doses — per EMA cumulative reports.
Global market · 2024
$7.8B
Flea, tick & heartworm prevention worldwide
Projected market · 2034
$14B+
Built on year-round dosing recommendations globally
Vet income from prescriptions
20%
Of total practice revenue — FTC, US (2015)
A $7.8 billion market built on routine
North America commands nearly
46% of global revenue. Europe accounts for roughly
28%. Asia-Pacific is the fastest-growing segment.
$14 billion by 2034 — and why
The market is forecast to nearly double over the next decade, driven by rising pet ownership, longer tick seasons due to climate shifts, and expansion into Asia-Pacific. This growth is built on year-round preventive dosing recommendations — a protocol that generates recurring monthly revenue regardless of actual seasonal risk in any given region.
Elanco alone — the company that bought Bayer's animal health division for $6.89 billion in 2020 — reported Pet Health revenue of $439 million in a single quarter of 2024.
The conflict no one is required to disclose
The FTC documented that prescription medications make up roughly 20% of a typical US veterinary practice's total income.
The same person diagnosing your pet also profits from the treatment they recommend.In human medicine, a structural firewall exists — doctors write prescriptions, pharmacies fill them. In veterinary medicine, no such separation is required anywhere in the world. And no transparency law anywhere requires vets or pharmaceutical companies to disclose their financial relationships.
United States
No lawSunshine Act covers human medicine only.
European Union
No lawNo equivalent transparency code for vet practice.
United Kingdom
No lawVMD regulates products. No disclosure requirement.
Japan
PartialClinical Research Act covers human pharma only.
China
No lawMARA regulates drugs. No financial disclosure framework.
Australia
No lawAPVMA oversees products. No transparency obligation.
↑ click any card to expand · click again to close
Who's selling it — and why that matters
The global flea, tick, and heartworm prevention market was valued at approximately $7.8 billion in 2024, projected to exceed $14 billion by 2034. North America accounts for nearly half. Europe follows at roughly 28%. Asia-Pacific is the fastest-growing segment.
Neither vets nor pharmaceutical companies are required to disclose their financial relationships with each other. That's true in Paris, in London, in New York, in Sydney — and in Tokyo, Shanghai, Mumbai, and Seoul. Across every major pet-owning market in the world, this gap exists. The transparency laws that do exist in human medicine — like the US Sunshine Act or Japan's Clinical Research Act disclosures — apply to human healthcare only. The animal health sector operates in a parallel world with no equivalent obligation, anywhere.
A case study in corporate accountability
K9 Advantix II was developed by Bayer — a German company, headquartered in Leverkusen. In 2020, Bayer sold its entire animal health division to Elanco Animal Health for $6.89 billion. New name on the box. Same formula. Accountability harder to trace.
The Bayer → Elanco trail · click each entry
2015
WHO classifies glyphosate as "probably carcinogenic"
Roundup's active ingredient. The clock starts ticking on Bayer globally.
The IARC — the WHO's cancer research body — classified glyphosate as Group 2A: probably carcinogenic to humans. Bayer had not yet acquired Monsanto. But the legal exposure was already being built. This classification opened the door to the lawsuits that would eventually cost Bayer nearly $11 billion.
2018
Bayer acquires Monsanto for $63B — and inherits Roundup
The same year, the FDA and EMA both issue neurological warnings on Bayer's isoxazoline class.
One year. Two massive liability events. Bayer finalised its $63 billion acquisition of Monsanto just as the first Roundup jury verdict came in. Simultaneously, the FDA issued its public isoxazoline safety alert, with the EMA's CVMP flagging the same products through its own surveillance. Both regulators pointed at Bayer products in the same calendar year.
2020
Bayer sells animal health division to Elanco for $6.89 billion
K9 Advantix II transfers. Same formula. Accountability harder to trace.
With Roundup litigation mounting, Bayer divested its entire animal health portfolio to Elanco Animal Health. The product didn't change. The formulation didn't change. What changed was the name on the packaging and the chain of accountability. That same year, the Project Jake Survey published its findings: 66.6% of dogs treated with isoxazolines had adverse reactions.
2025 – 2026
Georgia jury: $2.1B verdict. Then Bayer proposes $7.25B class settlement.
Total Roundup settlements approach $11 billion. Their position throughout: the product is safe.
In April 2025, a Georgia jury ordered Bayer to pay over $2 billion to a man who developed non-Hodgkin's lymphoma after 20 years of Roundup use at home. In March 2026, Bayer proposed a further $7.25 billion class settlement to resolve current and future claims. One company. Roundup. K9 Advantix II. Nearly $11 billion in settlements. One consistent message: trust us.
The pattern
Both products approved using company-submitted safety data
Standard industry practice — in the US, the EU, and everywhere else.
In the US, Bayer submitted its own safety data to the EPA and FDA to get its own products approved. In Europe, the same process runs through the EMA's centralised procedure. This is standard practice across the entire pharmaceutical industry — human and veterinary — in every regulatory market worldwide. The company that makes the product also generates the evidence used to approve it. That structural reality applies to every product on the shelf at your vet's clinic today.
The product didn't change when it moved to Elanco. The accountability just became harder to trace.
What to watch for — wherever you are
If your dog receives an isoxazoline-class medication, watch for seizures or tremors within 24 hours of dosing or at the 8–14 day mark, unexplained muscle twitching or shaking, loss of coordination or balance, and unusual lethargy or unresponsiveness.
European Union
Report via your national authority — ANMV (France), BVL (Germany), MEB (Netherlands), AEMPS (Spain).
All regions
You can report directly as a pet owner in most countries. You do not need your vet to do it for you.
Up next in this series
Part 2: The supplement strategy — what the research actually supports →
Read Part 2
Sources
FDA Isoxazoline Safety Alert (2018, updated 2021, 2023) · EMA CVMP cumulative adverse event reports · Project Jake Survey, Veterinary Medicine and Science (2020) · FDA adverse event records 2013–2017 · FTC Veterinary Medicine Report (2015) · Grand View Research, Straits Research market data (2024) · CNN / Courthouse News Roundup reporting (2025–2026) · Bayer/Elanco sale announcement (2020) · Hemopet EMA data analysis · VMD SARSS reporting scheme · Japan Clinical Research Act disclosure framework · ScienceDirect pharmaceutical advertising comparative review (2025)